What is Ometis-20?
Ometis-20 + SyrSpend SF Alka is a proton pump inhibitor that decreases the amount of acid produced in the stomach.
Ometis-20 + SyrSpend SF Alka is used to treat symptoms of gastroesophageal reflux disease (GERD) and other conditions caused by excess stomach acid. Ometis-20 + SyrSpend SF Alka is also used to promote healing of erosive esophagitis (damage to your esophagus caused by stomach acid).
Ometis-20 + SyrSpend SF Alka may also be given together with antibiotics to treat gastric ulcer caused by infection with Helicobacter pylori (H. pylori).
Over-the-counter (OTC) Ometis-20 + SyrSpend SF Alka is used to help control heartburn that occurs 2 or more days per week. Ometis-20 + SyrSpend SF Alka + SyrSpend SF Alka not for immediate relief of heartburn symptoms. OTC Ometis-20 + SyrSpend SF Alka must be taken on a regular basis for 14 days in a row.
Ometis-20 + SyrSpend SF Alka may also be used for purposes not listed in this medication guide.
Ometis-20 indications
Duodenal Ulcer (adults)
Ometis-20 is indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy.
Ometis-20 in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults.
Ometis-20 in combination with clarithromycin is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults.
Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.
Among patients who fail therapy, Ometis-20 with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted, and the clarithromycin package insert, Microbiology section.
Gastric Ulcer (Adults)
Ometis-20 is indicated for short-term treatment (4-8 weeks) of active benign gastric ulcer in adults.
Treatment Of Gastroesophageal Reflux Disease (GERD) (Adults and Pediatric Patients)
Symptomatic GERD
Ometis-20 is indicated for the treatment of heartburn and other symptoms associated with GERD in pediatric patients and adults for up to 4 weeks.
Erosive Esophagitis
Ometis-20 is indicated for the short-term treatment (4-8 weeks) of erosive esophagitis that has been diagnosed by endoscopy in pediatric patients and adults.
The efficacy of Ometis-20 used for longer than 8 weeks in these patients has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of erosive esophagitis or GERD symptoms (eg, heartburn), additional 4-8 week courses of Ometis-20 may be considered.
Maintenance Of Healing Of Erosive Esophagitis (Adults and Pediatric Patients)
Ometis-20 is indicated to maintain healing of erosive esophagitis in pediatric patients and adults.
Controlled studies do not extend beyond 12 months.
Pathological Hypersecretory Conditions (Adults)
Ometis-20 is indicated for the long-term treatment of pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults.
How should I use Ometis-20?
Use Ometis-20 delayed-release capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Ometis-20 delayed-release capsules comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Ometis-20 delayed-release capsules refilled.
- Take Ometis-20 delayed-release capsules by mouth before a meal or as directed by your doctor.
- Swallow Ometis-20 delayed-release capsules whole. Do not break, crush, chew, or open Ometis-20 delayed-release capsules before swallowing.
- If you have trouble swallowing the capsule, add 1 tablespoon of applesauce to an empty bowl. Open the capsule and empty the pellets onto the applesauce. Mix the pellets with the applesauce and swallow the mixture at once, followed by a glass of cool water. The applesauce used should not be hot and should be soft enough to be swallowed without chewing. Do not chew or crush the pellets. Do not store the mixture for further use.
- You may take antacids while you are taking Ometis-20 delayed-release capsules if you are directed to do so by your doctor.
- Continue to take Ometis-20 delayed-release capsules even if you feel well. Do not miss any doses.
- If you miss a dose of Ometis-20 delayed-release capsules, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Ometis-20 delayed-release capsules.
Uses of Ometis-20 in details
Use: Labeled Indications
Gastroesophageal reflux disease, erosive or nonerosive (Rx only):
Treatment of erosive esophagitis: Short-term treatment of erosive esophagitis (EE) due to acid-mediated gastroesophageal reflux disease (GERD) diagnosed by endoscopy in patients ≥1 year of age; short-term treatment (up to 6 weeks) of EE due to acid-mediated GERD in pediatric patients 1 month to <1 year of age.
Maintenance healing of erosive esophagitis: Maintenance healing of EE due to acid-mediated GERD in patients ≥1 year of age.
Symptomatic gastroesophageal reflux disease: Treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients ≥1 year of age.
Heartburn (OTC only): Treatment of frequent, uncomplicated heartburn (occurring ≥2 or more days per week) in adults.
Helicobacter pylori eradication (Rx only): Treatment of H. pylori infection and duodenal ulcer disease in adults as part of an appropriate combination regimen with antibiotics.
Peptic ulcer disease, treatment of duodenal or gastric ulcers (Rx only): Short-term treatment of active duodenal or gastric ulcers in adults.
Zollinger-Ellison syndrome (Rx only): Long-term treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome, in adults.
Off Label Uses
Aspiration prophylaxis in patients undergoing anesthesia
Data from several studies of varying methodologies (including randomized, double-blind, double-dummy, parallel-group trials) and a meta-analysis support the use of Ometis-20 for the prevention of aspiration in patients undergoing anesthesia. Studies were conducted in the elective surgery setting, including scheduled cesarean deliveries.
Based on the Surviving Sepsis Campaign international guidelines for the management of severe sepsis and septic shock, stress ulcer prophylaxis using a PPI is an effective and recommended option in select critically ill patients with GI bleeding risk factors.
Ometis-20 description
The active ingredient in Ometis-20 is a substituted benzimidazole. (RS)-5-methoxy-2(4-methoxy-3,5-dimethyl-2-pyridylmethylsulphinyl) benzimidazole, a compound that inhibits gastric acid secretion. Its empirical formula is C17H19N3O3S, with a molecular weight of 345.42. Ometis-20 is a white to off-white crystalline powder which melts with decomposition at about 155°C. It is a weak base, freely soluble in ethanol and methanol, and slightly soluble in acetone and isopropanol and very slightly soluble in water. The stability of Ometis-20 is a function of pH; it is rapidly degraded in acid media, but has acceptable stability under alkaline conditions.
Ometis-20 is a proton pump inhibitor. It inhibits secretion of gastric acid by irreversibly blocking the enzyme system of hydrogen/potassium adenosine triphosphatase (H+/K+ ATPase), the "proton pump" of the gastric parietal cell. It is used in conditions where inhibition of gastric acid secretion may be beneficial, including aspiration syndromes, dyspepsia, gastro-esophageal reflux disease, peptic ulcer disease and the Zollinger-Ellison syndrome.
Ometis-20 dosage
Ometis-20 Delayed-Release Capsules should be taken before eating. In the clinical trials, antacids were used concomitantly with Ometis-20.
Patients should be informed that the Ometis-20 Delayed-Release Capsule should be swallowed whole.
For patients unable to swallow an intact capsule, alternative administration options are available.
Short-Term Treatment Of Active Duodenal Ulcer
The recommended adult oral dose of Ometis-20 is 20 mg once daily. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy.
H. pylori Eradication For The Reduction Of The Risk Of Duodenal Ulcer Recurrence
Triple Therapy (Ometis-20/clarithromycin/amoxicillin)
The recommended adult oral regimen is Ometis-20 20 mg plus clarithromycin 500 mg plus amoxicillin 1000 mg each given twice daily for 10 days. In patients with an ulcer present at the time of initiation of therapy, an additional 18 days of Ometis-20 20 mg once daily is recommended for ulcer healing and symptom relief.
Dual Therapy (Ometis-20/clarithromycin)
The recommended adult oral regimen is Ometis-20 40 mg once daily plus clarithromycin 500 mg three times daily for 14 days. In patients with an ulcer present at the time of initiation of therapy, an additional 14 days of Ometis-20 20 mg once daily is recommended for ulcer healing and symptom relief.
Gastric Ulcer
The recommended adult oral dose is 40 mg once daily for 4-8 weeks.
Gastroesophageal Reflux Disease (GERD)
The recommended adult oral dose for the treatment of patients with symptomatic GERD and no esophageal lesions is 20 mg daily for up to 4 weeks. The recommended adult oral dose for the treatment of patients with erosive esophagitis and accompanying symptoms due to GERD is 20 mg daily for 4 to 8 weeks.
Maintenance Of Healing Of Erosive Esophagitis
The recommended adult oral dose is 20 mg daily. Controlled studies do not extend beyond 12 months.
Pathological Hypersecretory Conditions
The dosage of Ometis-20 in patients with pathological hypersecretory conditions varies with the individual patient. The recommended adult oral starting dose is 60 mg once daily. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Doses up to 120 mg three times daily have been administered. Daily dosages of greater than 80 mg should be administered in divided doses. Some patients with Zollinger-Ellison syndrome have been treated continuously with Ometis-20 for more than 5 years.
Pediatric Patients
For the treatment of GERD and maintenance of healing of erosive esophagitis, the recommended daily dose for pediatric patients 1 to 16 years of age is as follows:
| Patient Weight | Ometis-20 Daily Dose |
| 5 < 10 kg | 5 mg |
| 10 < 20 kg | 10 mg |
| ≥ 20 kg | 20 mg |
On a per kg basis, the doses of Ometis-20 required to heal erosive esophagitis in pediatric patients are greater than those for adults.
Alternative administrative options can be used for pediatric patients unable to swallow an intact capsule.
Alternative Administration Options
Ometis-20 is available as a delayed-release capsule or as a delayed-release oral suspension.
For patients who have difficulty swallowing capsules, the contents of a Ometis-20 Delayed-Release Capsule can be added to applesauce.
One tablespoon of applesauce should be added to an empty bowl and the capsule should be opened. All of the pellets inside the capsule should be carefully emptied on the applesauce. The pellets should be mixed with the applesauce and then swallowed immediately with a glass of cool water to ensure complete swallowing of the pellets. The applesauce used should not be hot and should be soft enough to be swallowed without chewing. The pellets should not be chewed or crushed. The pellets/applesauce mixture should not be stored for future use.
Ometis-20 For Delayed-Release
Oral Suspension should be administered as follows:
- Empty the contents of a 2.5 mg packet into a container containing 5 mL of water.
- Empty the contents of a 10 mg packet into a container containing 15 mL of water.
- Stir
- Leave 2 to 3 minutes to thicken.
- Stir and drink within 30 minutes.
- If any material remains after drinking, add more water, stir and drink immediately.
For patients with a nasogastric or gastric tube in place:
- Add 5 mL of water to a catheter tipped syringe and then add the contents of a 2.5 mg packet (or 15 mL of water for the 10 mg packet). It is important to only use a catheter tipped syringe when administering Ometis-20 through a nasogastric tube or gastric tube.
- Immediately shake the syringe and leave 2 to 3 minutes to thicken.
- Shake the syringe and inject through the nasogastric or gastric tube, French size 6 or larger, into the stomach within 30 minutes.
- Refill the syringe with an equal amount of water.
- Shake and flush any remaining contents from the nasogastric or gastric tube into the stomach.
How supplied
Dosage Forms And Strengths
Ometis-20 Delayed-Release Capsules, 10 mg, are opaque, hard gelatin, apricot and amethyst colored capsules, coded 606 on cap and Ometis-20 10 on the body.
Ometis-20 Delayed-Release Capsules, 20 mg, are opaque, hard gelatin, amethyst colored capsules, coded 742 on cap and Ometis-20 20 on the body.
Ometis-20 Delayed-Release Capsules, 40 mg, are opaque, hard gelatin, apricot and amethyst colored capsules, coded 743 on cap and Ometis-20 40 on the body.
Ometis-20 For Delayed-Release
Oral Suspension, 2.5 mg or 10 mg, is supplied as a unit dose packet containing a fine yellow powder, consisting of white to brownish Ometis-20 granules and pale yellow inactive granules.
Storage And Handling
Ometis-20 Delayed-Release Capsules, 10 mg, are opaque, hard gelatin, apricot and amethyst colored capsules, coded 606 on cap and Ometis-20 10 on the body. They are supplied as follows:
NDC 0186-0606-31 unit of use bottles of 30
Ometis-20 Delayed-Release Capsules, 20 mg, are opaque, hard gelatin, amethyst colored capsules, coded 742 on cap and Ometis-20 20 on body. They are supplied as follows:
NDC 0186-0742-31 unit of use bottles of 30
NDC 0186-0742-82 bottles of 1000
Ometis-20 Delayed-Release Capsules, 40 mg, are opaque, hard gelatin, apricot and amethyst colored capsules, coded 743 on cap and Ometis-20 40 on the body. They are supplied as follows:
NDC 0186-0743-31 unit of use bottles of 30
NDC 0186-0743-68 bottles of 100
Ometis-20 For Delayed-Release
Oral Suspension, 2.5 mg or 10 mg
, is supplied as a unit dose packet containing a fine yellow powder, consisting of white to brownish Ometis-20 granules and pale yellow inactive granules. Ometis-20 unit dose packets are supplied as follows:NDC 0186-0625-01 unit dose packages of 30: 2.5 mg packets
NDC 0186-0610-01 unit dose packages of 30: 10 mg packets
Storage
Store Ometis-20 Delayed-Release Capsules in a tight container protected from light and moisture. Store between 15°C and 30°C (59°F and 86°F).
Store Ometis-20 For Delayed-Release
Oral Suspension at 25°C (77°F); excursions permitted to 15 – 30°C (59 – 86°F).
AstraZeneca Pharmaceuticals LP Wilmington, DE 19850. Revised December 2014
Ometis-20 interactions
See also:
What other drugs will affect Ometis-20?
Effects of Ometis-20 on the Pharmacokinetics of Other Drugs: The following combination with Ometis-20 should be avoided: Ketoconazole and itraconazole.
Ometis-20 might influence the absorption of other drugs due to its effect on the gastric pH. The dissolution of ketoconazole tablets in the stomach is adversely affected if the pH of the gastric juice increases as a result of drug treatment (antacids, secretion-inhibiting agents, sucralfate). This leads to ineffective plasma concentrations of ketoconazole. During concomitant administration of Ometis-20 and itraconazole, the plasma concentration and area under the curve (AUC) of itraconazole are reduced by approximately 65%, probably as a result of poorer absorption, which is dependent on pH.
Ometis-20 inhibits the enzyme CYP2C19 and therefore, increased plasma levels of other drugs (diazepam, warfarin, phenytoin) metabolized via this enzyme might be expected. Monitoring is recommended during initiation or withdrawal of Ometis-20 in patients being treated with phenytoin, warfarin or other vitamin K antagonist.
During concomitant administration of clarithromycin or erythromycin and Ometis-20, the plasma concentrations of Ometis-20 were increased. The plasma concentrations of Ometis-20 are not influenced during concomitant administration with amoxicillin or metronidazole.
Concomitant administration of Ometis-20 (40 mg once daily) and atazanavir 300 mg/ritonavir 100 mg to healthy volunteers resulted in a marked reduction in total atazanavir exposure (approximately 75% reduction of AUC, Cmax and Cmin). An increase in the atazanavir dose to 400 mg did not compensate for the effect that Ometis-20 had on atazanavir exposure. Proton pump inhibitors including Ometis-20 should therefore not be administered concomitantly with atazanavir.
Concomitant administration of Ometis-20 and tacrolimus may increase the serum levels of tacrolimus. Monitoring of the plasma tacrolimus concentration is recommended when treatment with Ometis-20 is being initiated or discontinued. Ometis-20 (40 mg daily) increased the Cmax and AUC of voriconazole (CYP2C19 substrate) by 15% and 41%, respectively.
Effects of Other Drugs on the Pharmacokinetics of Ometis-20: Drugs inhibiting the enzymes CYP2C19 or CYP3A (HIV protease inhibitors, ketoconazole, itraconazole) might increase the plasma concentrations of Ometis-20. Voriconazole increases the AUC of Ometis-20 by 280%. In cases of concomitant treatment, an adjustment of the Ometis-20 dose should be considered for patients with considerable impaired hepatic function and in cases of long-term treatment.
Case reports, published population pharmacokinetic studies and retrospective analyses suggest that concomitant administration of PPIs and methotrexate (primarily at high doses) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate. However, no formal drug interaction studies of methotrexate with PPIs have been conducted.
No interactions between Ometis-20 and antacids, theophylline, caffeine, quinidine, lidocaine, propranolol, metoprolol or ethanol have been detected.
Ometis-20 side effects
See also:
What are the possible side effects of Ometis-20?
Clinical Trials Experience With Ometis-20 Monotherapy
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety data described below reflects exposure to Ometis-20 Delayed-Release Capsules in 3096 patients from worldwide clinical trials (465 patients from US studies and 2,631 patients from international studies). Indications clinically studied in US trials included duodenal ulcer, resistant ulcer, and Zollinger-Ellison syndrome. The international clinical trials were double blind and open-label in design. The most common adverse reactions reported (i.e., with an incidence rate ≥ 2%) from Ometis-20-treated patients enrolled in these studies included headache (6.9%), abdominal pain (5.2%), nausea (4.0%), diarrhea (3.7%), vomiting (3.2%), and flatulence (2.7%).
Additional adverse reactions that were reported with an incidence ≥ 1% included acid regurgitation (1.9%), upper respiratory infection (1.9%), constipation (1.5%), dizziness (1.5%), rash (1.5%), asthenia (1.3%), back pain (1.1%), and cough (1.1%).
The clinical trial safety profile in patients greater than 65 years of age was similar to that in patients 65 years of age or less.
The clinical trial safety profile in pediatric patients who received Ometis-20 Delayed-Release Capsules was similar to that in adult patients. Unique to the pediatric population, however, adverse reactions of the respiratory system were most frequently reported in both the 1 to < 2 and 2 to 16 year age groups (75.0% and 18.5%, respectively). Similarly, fever was frequently reported in the 1 to 2 year age group (33.0%), and accidental injuries were reported frequently in the 2 to 16 year age group (3.8%).
Clinical Trials Experience With Ometis-20 In Combination Therapy For H. pylori Eradication
In clinical trials using either dual therapy with Ometis-20 and clarithromycin, or triple therapy with Ometis-20, clarithromycin, and amoxicillin, no adverse reactions unique to these drug combinations were observed. Adverse reactions observed were limited to those previously reported with Ometis-20, clarithromycin, or amoxicillin alone.
Dual Therapy (Ometis-20/clarithromycin)
Adverse reactions observed in controlled clinical trials using combination therapy with Ometis-20 and clarithromycin (n = 346) that differed from those previously described for Ometis-20 alone were taste perversion (15%), tongue discoloration (2%), rhinitis (2%), pharyngitis (1%) and flu-syndrome (1%). (For more information on clarithromycin, refer to the clarithromycin prescribing information, Adverse Reactions section.)
Triple Therapy (Ometis-20/clarithromycin/amoxicillin)
The most frequent adverse reactions observed in clinical trials using combination therapy with Ometis-20, clarithromycin, and amoxicillin (n = 274) were diarrhea (14%), taste perversion (10%), and headache (7%). None of these occurred at a higher frequency than that reported by patients taking antimicrobial agents alone. (For more information on clarithromycin or amoxicillin, refer to the respective prescribing information, Adverse Reactions sections.)
Post-marketing Experience
The following adverse reactions have been identified during post-approval use of Ometis-20 Delayed-Release Capsules. Because these reactions are voluntarily reported from a population of uncertain size, it is not always possible to reliably estimate their actual frequency or establish a causal relationship to drug exposure.
Body As a Whole: Hypersensitivity reactions including anaphylaxis, anaphylactic shock, angioedema, bronchospasm, interstitial nephritis, urticaria,; fever; pain; fatigue; malaise;
Cardiovascular: Chest pain or angina, tachycardia, bradycardia, palpitations, elevated blood pressure, peripheral edema
Endocrine: Gynecomastia
Gastrointestinal: Pancreatitis (some fatal), anorexia, irritable colon, fecal discoloration, esophageal candidiasis, mucosal atrophy of the tongue, stomatitis, abdominal swelling, dry mouth, microscopic colitis. During treatment with Ometis-20, gastric fundic gland polyps have been noted rarely. These polyps are benign and appear to be reversible when treatment is discontinued.
Gastroduodenal carcinoids have been reported in patients with ZE syndrome on long-term treatment with Ometis-20. This finding is believed to be a manifestation of the underlying condition, which is known to be associated with such tumors.
Hepatic: Liver disease including hepatic failure (some fatal), liver necrosis (some fatal), hepatic encephalopathy hepatocellular disease, cholestatic disease, mixed hepatitis, jaundice, and elevations of liver function tests [ALT, AST, GGT, alkaline phosphatase, and bilirubin]
Infections and Infestations: Clostridium difficile associated diarrhea
Metabolism and Nutritional disorders: Hypoglycemia, hypomagnesemia, with or without hypocalcemia and/or hypokalemia, hyponatremia, weight gain
Musculoskeletal: Muscle weakness, myalgia, muscle cramps, joint pain, leg pain, bone fracture
Nervous System/Psychiatric: Psychiatric and sleep disturbances including depression, agitation, aggression, hallucinations, confusion, insomnia, nervousness, apathy, somnolence, anxiety, and dream abnormalities; tremors, paresthesia; vertigo
Respiratory: Epistaxis, pharyngeal pain
Skin: Severe generalized skin reactions including toxic epidermal necrolysis (some fatal), Stevens-Johnson syndrome, and erythema multiforme; photosensitivity; urticaria; rash; skin inflammation; pruritus; petechiae; purpura; alopecia; dry skin; hyperhidrosis
Special Senses: Tinnitus, taste perversion
Ocular: Optic atrophy, anterior ischemic optic neuropathy, optic neuritis, dry eye syndrome, ocular irritation, blurred vision, double vision
Urogenital: Interstitial nephritis, hematuria, proteinuria, elevated serum creatinine, microscopic pyuria, urinary tract infection, glycosuria, urinary frequency, testicular pain
Hematologic: Agranulocytosis (some fatal), hemolytic anemia, pancytopenia, neutropenia, anemia, thrombocytopenia, leukopenia, leucocytosis
Ometis-20 contraindications
See also:
What is the most important information I should know about Ometis-20?
You should not take this medication if you are allergic to Ometis-20 or to any other benzimidazole medication such as albendazole or mebendazole. Ometis-20 is not for immediate relief of heartburn symptoms.
Ask a doctor or pharmacist if it is safe for you to take Ometis-20 if you have liver disease or heart disease, or low levels of magnesium in your blood.
Some conditions are treated with a combination of Ometis-20 and antibiotics. Use all medications as directed by your doctor. Read the medication guide or patient instructions provided with each medication. Do not change your doses or medication schedule without your doctor's advice.
Take this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared.
Ometis-20 OTC (over-the-counter) should be taken for no longer than 14 days in a row. Allow at least 4 months to pass before you start another 14-day treatment.
Heartburn is often confused with the first symptoms of a heart attack. Seek emergency medical attention if you have chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, and a general ill feeling.
Active ingredient matches for Ometis-20:
| Unit description / dosage (Manufacturer) | Price, USD |
| Ometis-20 20mg CAP / 10 | $ 0.47 |
List of Ometis-20 substitutes (brand and generic names): | |
| Ometec (Mexico) | |
| Ometon (Lebanon, Portugal) | |
| Ometos | |
| Ometos 20 mg Capsule (Tosc International Pvt Ltd.) | $ 0.04 |
| Ometremp (Netherlands) | |
| Ometrix (Peru) | |
| Ometrix Amex (Peru) | |
| Ometron (Peru) | |
| OMETROY | |
| OMETROY TABLET 1 strip / 15 tablets each (Troikaa Pharmaceuticals Ltd) | $ 0.64 |
| Ometus | |
| Ometus 20mg CAP / 10 (Auztus Laboratories Pvt. Ltd.) | $ 0.43 |
| Ometus 20 mg Capsule (Auztus Laboratories Pvt. Ltd.) | $ 0.04 |
| Omev D | |
| Omev D 20+10 Capsule (Zota Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 0.05 |
| Omevar (India) | |
| Omevar 20mg CAP / 10 (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 0.46 |
| 20 mg x 10's (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 0.46 |
| Omevar 20 mg Capsule (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 0.05 |
| OMEVAR cap 20 mg x 10's (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 0.46 |
| Omevax (Venezuela) | |
| Omevell (Indonesia) | |
| Omevell 20 mg x 30's (Novell) | $ 33.48 |
| Omevex (Philippines) | |
| Omevex infusion / lyo 40 mg 5 x 1's (Livzon) | $ 10.56 |
| Omevin | |
| Omevin 20mg Capsule (Iatros Pharmaceuticals Pvt Ltd) | $ 0.01 |
| Omevingt (Vietnam) | |
| Omevingt 20 mg x 3 Blister x 10 Tablet, 25 Blister x 4 Tablet, Bottle 14 Tablet | |
| Omevingt 20 mg x 3 Blister x 10 Tablet | |
| Omevingt 20 mg x 25 Blister x 4 Tablet | |
| Omevingt 20 mg x 1 Bottle 14 Tablet | |
| Omex (Colombia, Serbia) | |
| Omex 20 mg Capsule (Symet Labs. Pvt. Ltd) | $ 0.05 |
| OMEX 20MG CAPSULE 1 strip / 10 capsules each (Symet Labs. Pvt. Ltd) | $ 0.55 |
| OMEX cap 20 mg x 15's (Symet Labs. Pvt. Ltd) | $ 0.78 |
| Omex 20mg Capsule (Symet Labs. Pvt. Ltd) | $ 0.05 |
| Omexac-20 (Philippines) | |
| Omexac-20/Omexac-40 (Philippines) | |
| Omexac-20 DR cap 20 mg 30's (Stallion Labs) | |
| Omexac-40 (Philippines) | |
| OMEY (India) | |
| 20 mg x 10's (Intas Laboratories Pvt Ltd) | $ 0.42 |
| Omey 20 mg Capsule (Intas Laboratories Pvt Ltd) | $ 0.04 |
| Omey 20mg CAP / 10 (Intas Laboratories Pvt Ltd) | $ 0.42 |
| OMEY cap 20 mg x 10's (Intas Laboratories Pvt Ltd) | $ 0.38 |
| OMEY cap 20 mg x 15's (Intas Laboratories Pvt Ltd) | $ 0.57 |
| Omey 20mg CAP / 10 (Intas Laboratories Pvt Ltd) | $ 0.42 |
| Omeya | |
| Omeya 20mg CAP / 10 | |
| Omez (Georgia, India, Malaysia, Myanmar, Peru, Romania, Russian Federation, South Africa, Venezuela, Vietnam) | |
| Capsule; Oral; Omeprazole 20 mg (Dr Reddy Laboratories Ltd) | |
| OMEZ Capsule/ Tablet / 20mg / 15 units (Dr Reddy Laboratories Ltd) | $ 0.90 |
| OMEZ Capsule/ Tablet / 40mg / 10 units (Dr Reddy Laboratories Ltd) | $ 0.96 |
| OMEZ Injection / 40mg / 1 units (Dr Reddy Laboratories Ltd) | $ 0.54 |
| OMEZ Capsule/ Tablet / 20mg / 10 units (Dr Reddy Laboratories Ltd) | $ 0.66 |
See 4748 substitutes for Ometis-20 | |
References
- DailyMed. "OMEPRAZOLE MAGNESIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "omeprazole". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "omeprazole". http://www.drugbank.ca/drugs/DB00338 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Ometis-20 are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Ometis-20. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
